C57BL/6JCya-Scara5em1flox/Cya
Common Name:
Scara5-flox
Product ID:
S-CKO-15006
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Scara5-flox
Strain ID
CKOCMP-71145-Scara5-B6J-VA
Gene Name
Product ID
S-CKO-15006
Gene Alias
4932433F15Rik; 4933425F03Rik; Tesr
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
14
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Scara5em1flox/Cya mice (Catalog S-CKO-15006) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000022610
NCBI RefSeq
NM_028903
Target Region
Exon 3
Size of Effective Region
~1.5 kb
Detailed Document
Overview of Gene Research
Scavenger receptor class A member 5 (SCARA5) is a gene that has been implicated in multiple biological processes and disease conditions. While its exact normal cellular functions are still being elucidated, it is believed to play important roles in pathways related to cell growth, migration, and invasion. Its dysregulation has been associated with the development and progression of various cancers, suggesting its significance in tumorigenesis [1,2,3,4,5,6,7,8,9].
In gastric cancer, SCARA5 expression is downregulated due to promoter methylation, and its overexpression suppresses tumor growth, migration, and invasion both in vitro and in xenograft models by inhibiting epithelial-mesenchymal transition (EMT) and inactivating MMP-2 and MMP-9 [1]. In colorectal cancer, bone marrow stromal cell-derived exosomes containing SCARA5 inhibit cancer cell growth and motility, and knockdown of SCARA5 in these exosomes promotes cell proliferation and movement. Exosomal SCARA5 also suppresses tumor growth in mouse xenografts by inactivating the PI3K/Akt pathway [3]. In bladder cancer, SCARA5 expression is downregulated, and its overexpression reduces cell viability, colony formation, invasion, and migration. It is a downstream factor of the PCAT29/miR-141 axis [4]. In oral squamous cell carcinoma, SCARA5 overexpression inhibits cell proliferation, induces apoptosis, and represses EMT by inactivating the STAT3 and PI3K/AKT signaling pathways [5]. In esophageal squamous cell carcinoma, SCARA5 is decreased, and its overexpression suppresses cell cycle, metastasis, and invasion by inducing ferroptosis through combining with ferritin light chain [6]. In nasopharyngeal carcinoma, SCARA5 is downregulated by promoter methylation, and its overexpression inhibits cell migration, invasion, and proliferation, and enhances sensitivity to chemotherapy [7]. In melanoma, decreased SCARA5 expression is associated with poor prognosis, and it is related to the level of immune infiltration [9].
In conclusion, SCARA5 is involved in multiple cancer-related biological processes such as cell growth, migration, invasion, and apoptosis. Its dysregulation contributes to the development and progression of various cancers. Research using in vivo models like xenograft mouse models has been crucial in understanding the role of SCARA5 in these disease conditions, providing insights into its potential as a biomarker and therapeutic target for cancer treatment.
References：
1. Zhang, Hangyu, Liu, Changgang, Wang, Xinbo, Wang, Yongfang, Zheng, Jie. 2021. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. In Journal of Cancer, 12, 2412-2421. doi:10.7150/jca.52426. https://pubmed.ncbi.nlm.nih.gov/33758617/
2. Flockerzi, Fidelis Andrea, Hohneck, Johannes, Saar, Matthias, Bohle, Rainer Maria, Stahl, Phillip Rolf. 2023. SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis. In Diagnostics (Basel, Switzerland), 13, . doi:10.3390/diagnostics13132211. https://pubmed.ncbi.nlm.nih.gov/37443605/
3. Fang, Yu, Wu, Feng, Shang, Guoyin, Yin, Changqing. 2023. SCARA5 in bone marrow stromal cell-derived exosomes inhibits colorectal cancer progression by inactivating the PI3K/Akt pathway. In Genomics, 115, 110636. doi:10.1016/j.ygeno.2023.110636. https://pubmed.ncbi.nlm.nih.gov/37150230/
4. Lu, Xin-Sheng, Huang, Meng-Long, Chen, Li-Bo, Huang, Zhong-Xin, Liu, Shi-Min. 2023. SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer. In Genomics, 115, 110667. doi:10.1016/j.ygeno.2023.110667. https://pubmed.ncbi.nlm.nih.gov/37315873/
5. Huang, Juan, Lv, Chunhua, Zhao, Baoyu, Ji, Zhongqian, Gao, Zhenran. 2023. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways. In Open medicine (Warsaw, Poland), 18, 20230627. doi:10.1515/med-2023-0627. https://pubmed.ncbi.nlm.nih.gov/36785765/
6. Liu, Yanqun, Xiong, Rong, Xiao, Ting, Song, Guiqin, Liu, Kang. 2022. SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain. In BMC cancer, 22, 1304. doi:10.1186/s12885-022-10414-9. https://pubmed.ncbi.nlm.nih.gov/36513999/
7. Jiang, Xianyao, Jiang, Yu, An, Deqiang, Ji, Ping, Yang, Yucheng. 2023. Methylated tumor suppressor gene SCARA5 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma. In Epigenomics, 15, 635-650. doi:10.2217/epi-2023-0154. https://pubmed.ncbi.nlm.nih.gov/37554122/
8. Liu, J, Zeng, M L, Shi, P C, Zhang, J L, Xie, Y P. . SCARA5 is a Novel Biomarker in Colorectal Cancer by Comprehensive Analysis. In Clinical laboratory, 66, . doi:10.7754/Clin.Lab.2019.191015. https://pubmed.ncbi.nlm.nih.gov/32658413/
9. Ni, Qinggan, Li, Xia, Huang, Hua, Ge, Zili. 2023. Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis. In Frontiers in oncology, 13, 1015358. doi:10.3389/fonc.2023.1015358. https://pubmed.ncbi.nlm.nih.gov/37035142/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen